138 related articles for article (PubMed ID: 37488476)
21. Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
Katsube T; Shimizu R; Fukuhara T; Kano T; Wajima T
Clin Pharmacokinet; 2019 Nov; 58(11):1469-1482. PubMed ID: 31055790
[TBL] [Abstract][Full Text] [Related]
22. Relationship between response to lusutrombopag and splenic volume.
Uojima H; Arase Y; Itokawa N; Atsukawa M; Satoh T; Miyazaki K; Hidaka H; Sung JH; Kako M; Tsuruya K; Kagawa T; Iwakiri K; Horie R; Koizumi W
World J Gastroenterol; 2018 Dec; 24(46):5271-5279. PubMed ID: 30581275
[TBL] [Abstract][Full Text] [Related]
23. Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
Orme ME; Bentley R; Marcella S; Peck-Radosavljevic M; Perard R; Wedemeyer H; Yoshiji H; Agarwal K; Dusheiko G
Adv Ther; 2022 Sep; 39(9):4169-4188. PubMed ID: 35836089
[TBL] [Abstract][Full Text] [Related]
24. The Thrombopoietin Receptor Agonist Lusutrombopag Is Effective for Patients with Chronic Liver Disease and Impaired Renal Function.
Takeuchi H; Furuichi Y; Yoshimasu Y; Kasai Y; Abe M; Sugimoto K; Itoi T
J Nippon Med Sch; 2021 Jan; 87(6):325-333. PubMed ID: 32238734
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures.
Nishida Y; Kawaoka T; Imamura M; Namba M; Fujii Y; Uchikawa S; Ohya K; Daijo K; Teraoka Y; Morio K; Fujino H; Nakahara T; Yamauchi M; Hiramatsu A; Tsuge M; Aikata H; Takahashi S; Hayes CN; Fukuhara T; Tsuji K; Arataki K; Nagaoki Y; Aisaka Y; Kamada K; Kodama H; Chayama K
Intern Med; 2021 Mar; 60(6):829-837. PubMed ID: 33087674
[TBL] [Abstract][Full Text] [Related]
26. Relationship between baseline clinical characteristics and efficacy of lusutrombopag in thrombocytopenic patients with chronic liver disease:
Tanaka K; Baba T; Yoshida M; Iguchi M; Sonoyama T; Fukuhara T; Kano T
Curr Med Res Opin; 2022 Feb; 38(2):303-310. PubMed ID: 34904508
[TBL] [Abstract][Full Text] [Related]
27. A single course of lusutrombopag for multiple invasive procedures in cirrhosis-associated thrombocytopenia: A case series.
Biolato M; Vitale F; Marrone G; Miele L; Grieco A
Medicine (Baltimore); 2022 Nov; 101(44):e31429. PubMed ID: 36343065
[TBL] [Abstract][Full Text] [Related]
28. Lusutrombopag has slightly stronger effects on patients with mild thrombocytopenia compared with those with severe thrombocytopenia: A multicenter propensity score matching study.
Furuichi Y; Takeuchi H; Uojima H; Atsukawa M; Arai T; Arase Y; Kako M; Hidaka H; Itoi T
J Hepatobiliary Pancreat Sci; 2022 Apr; 29(4):439-448. PubMed ID: 34953107
[TBL] [Abstract][Full Text] [Related]
29. Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance.
Sasaki R; Shiino C; Imawari M; Bentley R; Cai B; Yoshida M; Afdhal N
Hepatol Res; 2019 Oct; 49(10):1169-1181. PubMed ID: 31228221
[TBL] [Abstract][Full Text] [Related]
30. [Long term (5 years) outcome of radiofrequency ablation for hepatocellular carcinoma in 256 cases].
Chen MH; Yan K; Yang W; Gao W; Dai Y; Huo L; Zhang H; Huang XF
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):671-2. PubMed ID: 16378128
[TBL] [Abstract][Full Text] [Related]
31. Minimally invasive surgery versus radiofrequency ablation for single subcapsular hepatocellular carcinoma ≤ 2 cm with compensated liver cirrhosis.
Lin CH; Ho CM; Wu CH; Liang PC; Wu YM; Hu RH; Lee PH; Ho MC
Surg Endosc; 2020 Dec; 34(12):5566-5573. PubMed ID: 31993821
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy of radiofrequency ablation to treat advanced hepatocellular carcinoma].
Wu J; Chen MH; Yang W; Wu W; Yan K
Zhonghua Gan Zang Bing Za Zhi; 2012 Apr; 20(4):256-60. PubMed ID: 22964144
[TBL] [Abstract][Full Text] [Related]
33. Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease.
Khemichian S; Terrault NA
Semin Thromb Hemost; 2020 Sep; 46(6):682-692. PubMed ID: 32820479
[TBL] [Abstract][Full Text] [Related]
34. Lusutrombopag: A Review in Thrombocytopenia in Patients with Chronic Liver Disease Prior to a Scheduled Procedure.
Shirley M; McCafferty EH; Blair HA
Drugs; 2019 Oct; 79(15):1689-1695. PubMed ID: 31529283
[TBL] [Abstract][Full Text] [Related]
35. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial.
Kim TH; Koh YH; Kim BH; Kim MJ; Lee JH; Park B; Park JW
J Hepatol; 2021 Mar; 74(3):603-612. PubMed ID: 33031846
[TBL] [Abstract][Full Text] [Related]
36. Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: A retrospective single-center study.
Kawaratani H; Tsuji Y; Ishida K; Kaya D; Kubo T; Fujinaga Y; Sawada Y; Sato S; Takaya H; Kaji K; Namisaki T; Moriya K; Akahane T; Yoshiji H
Hepatol Res; 2020 Sep; 50(9):1101-1105. PubMed ID: 32558192
[TBL] [Abstract][Full Text] [Related]
37. Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching.
Furuichi Y; Takeuchi H; Yoshimasu Y; Kasai Y; Abe M; Itoi T
Hepatol Res; 2020 Sep; 50(9):1062-1070. PubMed ID: 32510789
[TBL] [Abstract][Full Text] [Related]
38. Prospective observational study of low thresholds for platelet transfusion in adult dengue patients.
Thomas L; Kaidomar S; Kerob-Bauchet B; Moravie V; Brouste Y; King JP; Schmitt S; Besnier F; Abel S; Mehdaoui H; Plumelle Y; Najioullah F; Fonteau C; Richard P; Césaire R; Cabié A
Transfusion; 2009 Jul; 49(7):1400-11. PubMed ID: 19320862
[TBL] [Abstract][Full Text] [Related]
39. Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia.
Napolitano G; Iacobellis A; Merla A; Niro G; Valvano MR; Terracciano F; Siena D; Caruso M; Ippolito A; Mannuccio PM; Andriulli A
Eur J Intern Med; 2017 Mar; 38():79-82. PubMed ID: 27989373
[TBL] [Abstract][Full Text] [Related]
40. Percutaneous radiofrequency ablation of hepatocellular carcinoma in cirrhosis: analysis of complications in a single centre over 20 years.
Giorgio A; Merola MG; Montesarchio L; Merola F; Gatti P; Coppola C; Giorgio V; Calisti G
Br J Radiol; 2017 Jun; 90(1074):20160804. PubMed ID: 28402124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
